Transbody against virus core protein potently inhibits hepadnavirus replication in vivo: evidence from a duck model of hepatitis B virus
Authors:
- 7 June 2017
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (14) , 2261-2272
Abstract
Background and Purpose: The therapeutic management of hepatitis B virus (HBV) infections remains challenging, and novel antiviral strategies are urgently required. The HBV transbody, a monoclonal antibody (MAb) against human HBcAg coupled with the trans‐activator of transcription protein transduction domain (TAT PTD), was previously shown to possess cell‐penetrating ability and potent antiviral activity in vitro. The purpose of the present study was to evaluate the antiviral activity of the HBcMAb‐TAT PTD conjugate in vivo in a duck model of HBV.Experimental Approach: Female Peking ducks were injected i.p. with 0.03‐0.3 mg·kg−1·day−1 of the DHBV transbody (DHBcMAb‐TAT PTD conjugate) for 30 days. Serum DHBV DNA levels and liver DHBV DNA and covalently closed circular DNA (cccDNA) loads were determined at scheduled time points. Immunohistological examination of DHBcAg in the duck liver was also performed.Key Results: The DHBV transbody significantly reduced the serum and liver DHBV DNA levels at doses of 0.1 and 0.3 mg·kg−1·day−1 and liver cccDNA levels at a dose of 0.3 mg·kg−1·day−1 after 30 days of treatment. The suppressive effects of the DHBV transbody at 0.3 mg·kg−1·day−1 on the serum and liver DHBV DNA and liver cccDNA levels remained significant, even at 15 days after treatment cessation. Similarly, immunohistochemistry of liver sections revealed decreased DHBcAg levels within hepatocytes 15 days after treatment termination.Conclusions and Implications: The DHBV transbody inhibits DHBV replication and possesses potent anti‐DHBV activities in vivo. The cell‐permeable antibody against the virus core antigen may be developed as a novel treatment for patients with hepadnavirus infections.Keywords
Funding Information
- National Natural Science Foundation of China (81101260, 81272448)
This publication has 40 references indexed in Scilit:
- Experimental design and analysis and their reporting: new guidance for publication in BJPBritish Journal of Pharmacology, 2015
- Humanized-VH/VHH that inhibit HCV replication by interfering with the virus helicase activityJournal of Virological Methods, 2013
- Nucleic Acid Polymers Prevent the Establishment of Duck Hepatitis B Virus Infection In VivoAntimicrobial Agents and Chemotherapy, 2013
- Development and application of a universal Taqman real-time PCR for quantitation of duck hepatitis B virus DNAJournal of Virological Methods, 2013
- A Human Single Chain Transbody Specific to Matrix Protein (M1) Interferes with the Replication of Influenza A VirusBioconjugate Chemistry, 2010
- Epidemiology of Hepatitis B and C Viruses: A Global OverviewClinics in Liver Disease, 2010
- In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medikActa Pharmacologica Sinica, 2007
- Influence of protein transduction domains on intracellular delivery of macromoleculesExpert Opinion on Drug Delivery, 2006
- Duck Hepatitis B Virus: An Invaluable Model System for HBV Infection2004
- Characterization of Age- and Dose-Related Outcomes of Duck Hepatitis B Virus InfectionVirology, 1998